Daniela Diverio

List of Publications by Year
in descending order

40 papers	887 citations	933447 10 h-index	477307 29 g-index
40 all docs	40 docs citations	40 times ranked	1161 citing authors

#	Article	IF	Citations
1	Digital droplet PCR as a predictive tool for successful discontinuation outcome in chronic myeloid leukemia: Is it time to introduce it in the clinical practice?. Critical Reviews in Oncology/Hematology, 2021, 157, 103163.	4.4	10
2	Real-life evaluation of potential candidates for treatment discontinuation in chronic myeloid leukemia: the impact of age and long-term follow-up. Leukemia and Lymphoma, 2021, 62, 1026-1027.	1.3	4
3	Long-term follow-up of late chronic phase chronic myeloid leukemia patients treated with imatinib after interferon failure: a single center experience. Leukemia and Lymphoma, 2021, 62, 2261-2266.	1.3	0
4	Real-life comparison of nilotinib versus dasatinib as second-line therapy in chronic phase chronic myeloid leukemia patients. Annals of Hematology, 2021, 100, 1213-1219.	1.8	4
5	Outcome of relapsed/refractory acute promyelocytic leukaemia in children, adolescents and young adult patients â€" a 25â€year Italian experience. British Journal of Haematology, 2021, 195, 278-283.	2.5	4
6	Myeloid Sarcoma: Diagnostic and Treatment Tools from a Monocentric Retrospective Experience. Acta Haematologica, 2021, , 1-5.	1.4	3
7	Predictive factors for response and survival in elderly acute myeloid leukemia patients treated with hypomethylating agents: a real-life experience. Annals of Hematology, 2020, 99, 2405-2416.	1.8	11
8	NPM1 MUTATED, BCR-ABL1 POSITIVE MYELOID NEOPLASMS: REVIEW OF LITERATURE. Mediterranean Journal of Hematology and Infectious Diseases, 2020, 12, e2020083.	1.3	6
9	Switch from branded to generic imatinib: impact on molecular responses and safety in chronic-phase chronic myeloid leukemia patients. Annals of Hematology, 2020, 99, 2773-2777.	1.8	2
10	Digital droplet PCR at the time of TKI discontinuation in chronicâ€phase chronic myeloid leukemia patients is predictive of treatmentâ€free remission outcome. Hematological Oncology, 2019, 37, 652-654.	1.7	17
11	Incidence of Clinically Significant (â‰10 g/dL) Late Anemia in Elderly Patients with Newly Diagnosed Chronic Myeloid Leukemia Treated with Imatinib. Oncology Research and Treatment, 2019, 42, 660-664.	1.2	2
12	Atypical Chronic Myeloid Leukemia in a Patient with Aplastic Anemia. Acta Haematologica, 2019, 142, 185-186.	1.4	1
13	Ten-year outcome of chronic-phase chronic myeloid leukemia patients treated with imatinib in real life. Annals of Hematology, 2019, 98, 1891-1904.	1.8	10
14	Risk-adapted treatment of acute promyelocytic leukemia: results from the International Consortium for Childhood APL. Blood, 2018, 132, 405-412.	1.4	46
15	Prolonged treatment with arsenic trioxide (ATO) and all-trans-retinoic acid (ATRA) for relapsed acute promyelocytic leukemia previously treated with ATRA and chemotherapy. Annals of Hematology, 2018, 97, 1797-1802.	1.8	20
16	Clinical results according to age in patients with chronic myeloid leukemia receiving imatinib frontline: The younger, the later, the worse?. European Journal of Haematology, 2018, 101, 578-584.	2.2	3
17	Prognostic factors associated with a stable MR4.5 achievement in chronic myeloid leukemia patients treated with imatinib. Oncotarget, 2018, 9, 7534-7540.	1.8	19
18	Five Years after Frontline Tyrosine-Kinase Inhibitor (TKI) Treatment Initiation for Chronic Myeloid Leukemia: What Does It Happen in a Real-Life Setting?. Blood, 2018, 132, 1746-1746.	1.4	0

#	Article	IF	Citations
19	Overall Survival and Response Rates after a 10-Year Follow-up of Chronic Myeloid Leukemia Patients in Chronic Phase Treated with Imatinib in a Real-Life Practice. Blood, 2018, 132, 1741-1741.	1.4	0
20	Clinical and Prognostic Features of Essential Thrombocythemia: Comparison of Who 2001 Versus Who 2008/2016 Criteria in a Large Single Center Cohort. Blood, 2018, 132, 5464-5464.	1.4	0
21	Timing and deepness of response to tyrosine kinase inhibitors as a measure of potential treatment discontinuation in chronic myeloid leukemia patients managed in the realâ€life. American Journal of Hematology, 2017, 92, E668-E670.	4.1	7
22	Very late relapse in a patient with acute promyelocytic leukemia (APL) rescued with a chemotherapy-free protocol. Leukemia and Lymphoma, 2017, 58, 999-1001.	1.3	6
23	Independent prognostic impact of CD15 on complete remission achievement in patients with acute myeloid leukemia. Hematological Oncology, 2017, 35, 804-809.	1.7	5
24	Discontinuation of alpha-interferon treatment in patients with chronic myeloid leukemia in long-lasting complete molecular response. Leukemia and Lymphoma, 2016, 57, 99-102.	1.3	13
25	Introducing biological features at diagnosis improves the relapse risk stratification in patients with acute promyelocytic leukemia treated with <scp>ATRA</scp> and chemotherapy. American Journal of Hematology, 2015, 90, E181-2.	4.1	2
26	Event-Free Survival According to Age in Patients with Chronic Myeloid Leukemia Receiving Imatinib Frontline: The Younger, the Later, the Worse?. Blood, 2015, 126, 4038-4038.	1.4	1
27	Early Response Does Not Impact on the Long-Term Outcome of Children and Adolescents with Chronic Myeloid Leukemia Treated with High-Dose Imatinib. the Italian Experience. Blood, 2015, 126, 2788-2788.	1.4	0
28	CALR mutations in patients with essential thrombocythemia diagnosed in childhood and adolescence. Blood, 2014, 123, 3677-3679.	1.4	22
29	Exclusion Criteria In The Dasision and Enestnd Trials: Which Could Their Impact Be On The Front-Line Treatment Of a â€œReal-lifeâ€•Patient Population With Chronic Myelogenous Leukemia?. Blood, 2013, 122, 4002-4002.	1.4	1
30	FLT3-ITD Internal Tandem Duplication Confers Poor Prognosis In Patients With Acute Promyelocytic Leukemia Treated With The AIDA Protocols. Long-Term Follow-Up Analysis. Blood, 2013, 122, 1336-1336.	1.4	0
31	AIDA 0493 protocol for newly diagnosed acute promyelocytic leukemia: very long-term results and role of maintenance. Blood, 2011, 117, 4716-4725.	1.4	173
32	Complete Cytogenetic Response After 3 Months Is a Very Early Indicator of Good Response to Imatinib As Front-Line Treatment in Chronic Myelogenous Leukemia,. Blood, 2011, 118, 3783-3783.	1.4	2
33	Clinical Features of Idiopathic Erythrocytosis Compared to Polycythemia Vera JAK-2 V617F Positive and Negative Patients. Blood, 2011, 118, 5172-5172.	1.4	0
34	Front-line treatment of acute promyelocytic leukemia with AIDA induction followed by risk-adapted consolidation for adults younger than 61 years: results of the AIDA-2000 trial of the GIMEMA Group. Blood, 2010, 116, 3171-3179.	1.4	290
35	GIMEMA-AIEOP AIDA Protocols for the Treatment of Newly Diagnosed Acute Promyelocytic Leukemia (APL) In Children: Analysis of 247 Patients Enrolled In Two Sequential Italian Multicenter Trials. Blood, 2010, 116, 871-871.	1.4	7
36	Mlecular Monitoring of Acute Myeloid Leukemia Patients Carrying Nucleophosmin (NPM1) Mutations Undergoing An Autologous Peripheral Blood Stem Cell Transplantation. Blood, 2008, 112, 4864-4864.	1.4	0

#	Article	IF	Citations
37	Imatinib Mesylate Induces High Complete Cytogenetic and Molecular Response Rates in Children and Adolescents with Philadelphia Chromosome-Positive (Ph+) Chronic Myelogenous Leukemia (CML) in Chronic Phase (CP). Blood, 2008, 112, 4273-4273.	1.4	0
38	Imatinib Mesylate Therapy in Late Ph+ Chronic Myeloid Leukemia Patients in Stable Complete Cytogenetic Response after Interferon-Alpha Results in a Very High Complete Molecular Response Rate.. Blood, 2006, 108, 2158-2158.	1.4	0
39	GIMEMA-AIEOPAIDA protocol for the treatment of newly diagnosed acute promyelocytic leukemia (APL) in children. Blood, 2005, 106, 447-453.	1.4	196
40	Mechanism of Altered Nucleo-Cytoplasmic Traffic of Nucleophosmin in Acute Myelogenous Leukemia Carrying Exon-12 NPM Mutations (NPMc+ AML).. Blood, 2005, 106, 4396-4396.	1.4	0